ASMB Assembly Corp: מקדם חוב לטווח ארוך להון

Assembly Biosciences develops advanced treatments for chronic hepatitis B, leveraging the study of core protein inhibitors. The company is building a global network to combat viruses, aiming for the complete eradication of the disease. This price chart on GURU.Markets shows the metric at 0.01, while partners' certified capacities are ready for the seamless production of new medication batches.

Assembly Biosciences focuses on developing genetic cures for chronic hepatitis B, which requires significant R&D capital expenditures. This long-term debt-to-equity coverage ratio measures the proportion of liabilities with a maturity of over one year relative to equity, allowing investors to assess the company's financial stability and the risk of default regarding the long-term financing of innovative developments.